You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Some of the firms will receive money to speed up test development, while others will use the funds to expand their testing and manufacturing capacity.
The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.
In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.
The total relief package totals $484 billion, including $11 billion for states, localities, territories, tribes, and employers to scale up SARS-CoV-2 testing.
The Bill & Melinda Gates Foundation will also provide support to winners of the challenge, which may include a grant of up to $500,000.
Framingham, Massachusetts-based Kephera's tests is intended to be used to differentiate neurocysticercosis from other causes of seizures in patients.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
Specific Diagnostics said it plans to apply CE marking to the Reveal system next year, followed by submission to the FDA for 510(k) clearance.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.